U.S. law firm Kaplan Fox & Kilsheimer LLP has announced it is investigating potential securities law violations at Cellebrite DI Ltd. (NASDAQ: CLBT) following a significant earnings miss and abrupt leadership change. On August 13, 2026, Cellebrite reported second-quarter Annual Recurring Revenue of $507.8 million, falling short of its own guidance range, and simultaneously replaced its CEO effective immediately. Cellebrite shares fell $4.45, or 29%, to close at $10.80 on the same day. Investors who suffered losses may be watching this investigation closely.

Key Points

  • Cellebrite DI Ltd. (NASDAQ: CLBT) is the subject of a securities law investigation by Kaplan Fox & Kilsheimer LLP
  • Q2 Annual Recurring Revenue of $507.8 million missed the low end of company guidance of $510 million to $513 million
  • Cellebrite cut full-year ARR guidance by roughly $15 million at the midpoint and announced an immediate CEO transition from Tom Hogan to Shiv Ramji
  • Investors will be watching whether the investigation advances toward formal legal proceedings

Cellebrite Q2 ARR Miss and Guidance Cut Trigger Investor Scrutiny

Cellebrite reported second-quarter total Annual Recurring Revenue of $507.8 million on August 13, 2026, missing the lower end of its previously stated guidance range of $510 million to $513 million. The company also reduced its full-year ARR guidance by approximately $15 million at the midpoint. Management attributed the shortfall to what it described as "a foreign entity permit requirement, which is applied to cloud technology," stating this delayed certain deals. The combination of missed targets and a reduced outlook drew immediate attention from investors and legal observers.

Abrupt CEO Replacement Compounds Market Concerns at Cellebrite

Alongside its earnings disclosure, Cellebrite announced that CEO Tom Hogan was being replaced by Shiv Ramji, effective immediately. The release states that the leadership change was simultaneous with the quarterly results announcement, a timing that compounded negative investor sentiment. Executive transitions of this nature, particularly when announced alongside a guidance reduction, often prompt heightened scrutiny of a company's internal governance and prior disclosures. Kaplan Fox's investigation appears to focus on whether securities law obligations were fully met in the period leading up to these announcements.

Kaplan Fox Investigation Scope and Firm Background

Kaplan Fox & Kilsheimer LLP, founded in 1956 and headquartered in New York, describes itself as a nationally recognised plaintiffs' securities litigation firm. The firm states it has recovered more than $10 billion for clients across securities, antitrust, and consumer protection matters. The investigation into Cellebrite is focused on potential securities violations and is at an early stage. The announcement notes that contacting the firm does not create an attorney-client relationship, and that past results do not guarantee future outcomes.